Table 4.
Differences in Adverse Reactions of Live-Attenuated Oxford/AstraZeneca COVID-19 Vaccination Between Hyperthyroid (n=31) and Non-Hyperthyroid (n=2985) Groups
| Sign Effect | Category | 1st Dose | 2nd Dose | ||||||
|---|---|---|---|---|---|---|---|---|---|
| Hyperthyroid (n=31) | Non-Hyperthyroid (n=2985) | RR (95% CI) | p-value | Hyperthyroid (n=31) | None Hyperthyroid (n=2985) | RR (95% CI) | p-value | ||
| n(%) | n(%) | n(%) | n(%) | ||||||
| Within 30 minutes | Fever, mild headache or high grade fever, severe headache | 2(6.5) | 36(1.2) | 1.1 (0.963 to 1.158) | 0.051 | 0(0) | 2(0.1) | - | - |
| Chest discomfort or breathing difficulties | - | - | - | - | - | - | - | - | |
| Nausea or vomiting (no more than 5 times) | 0(0) | 5(0.2) | - | - | - | - | - | - | |
| Skin rash /urticaria | 0(0) | 6(0.2) | - | - | 0(0) | 2(0.1) | - | - | |
| Pain, swelling, redness and warmth at the injection site | 2(6.5) | 16(0.5) | 12.8 (2.814 to 58.21) | 0.001* | - | - | - | - | |
| Within 6 hours | Fever, mild headache or high grade fever, severe headache | 6(19.4) | 255(8.5) | 2.6 (1.04 to 6.321) | 0.04* | 0(0) | 50(1.7) | - | - |
| Chest discomfort or breathing difficulties | - | - | - | - | - | - | - | - | |
| Nausea or vomiting (no more than 5 times) | 0(0) | 21(0.7) | - | - | 0(0) | 3(0.1) | - | - | |
| Skin rash /urticaria | 0(0) | 25(0.8) | - | - | 0(0) | 4(0.2) | - | - | |
| Pain, swelling, redness and warmth at the injection site | 2(6.5) | 71(2.4) | 2.8 (0.663 to 12.09) | 0.16 | 0(0) | 18(0.6) | - | - | |
| Within 24 hours | Fever, mild headache or high grade fever, severe headache | 13(41.9) | 925(31) | 0.7 (0.487 to 1.22) | 0.194 | 5(16.6) | 540(18.1) | 0.97 (0.836to1.141) | 0.778 |
| Chest discomfort or breathing difficulties | 0(0) | 3(0.1) | - | - | - | - | - | - | |
| Nausea or vomiting (no more than 5 times) | 0(0) | 65(2.2) | - | - | 0(0) | 13(0.4) | - | - | |
| Skin rash /urticaria | 2(6.5) | 83(2.8) | 1 (0.947 to 1.140) | 0.234 | 0(0) | 18(0.6) | - | - | |
| Pain, swelling, redness and warmth at the injection site | 7(22.6) | 398(13.3) | 1.1 (0.925 to1.355) | 0.14 | 3(9.7) | 178(6) | 1.1 (0.927to1.169) | 0.392 | |
| After 24 hours | Fever, mild headache or high grade fever, severe headache | 4(12.9) | 429(14.4) | 0.9 (0.858 to 1.27) | 0.817 | 4(12.9) | 296(9.9) | 1 (0.903to1.185) | 0.582 |
| Chest discomfort or breathing difficulties | 0(0) | 4(0.1) | - | - | - | - | - | - | |
| Nausea or vomiting (no more than 5 times) | 0(0) | 34(1.1) | - | - | 0(0) | 10(0.3) | - | - | |
| Skin rash /urticaria | 0(0) | 56(1.9) | - | - | 0(0) | 18(0.6) | - | - | |
| Pain, swelling, redness and warmth at the injection site | 4(12.9) | 211(7.1) | 1.1 (0.931 to 1.222) | 0.217 | 3(9.7) | 140(4.7) | 1.1 (0.94to1.438) | 0.205 | |
| Within 3 days | Fever, mild headache or high grade fever, severe headache | 4(12.9) | 416(13.9) | 0.9 (0.319 to 2.628) | 0.869 | 4(12.9) | 294(9.8) | 1.4 (0.471to3.902) | 0.572 |
| Chest discomfort or breathing difficulties | 0(0) | 3(0.1) | - | - | - | - | - | - | |
| Nausea or vomiting (no more than 5 times) | 0(0) | 30(1) | - | - | 0(0) | 10(0.3) | - | - | |
| Skin rash /urticaria | 0(0) | 49(1.6) | - | - | 0(0) | 14(0.5) | - | - | |
| Pain, swelling, redness and warmth at the injection site | 4(12.8) | 208(7) | 2 (0.686 to 5.706) | 0.207 | 3(9.7) | 138(4.6) | 2.2 (0.664to7.36) | 0.196 | |
| Within 7 days | Fever, mild headache or high grade fever, severe headache | 4(12.9) | 428(14.3) | 0.9 (0.308 to 2.542) | 0.821 | 4(12.9) | 296(9.9) | 1 (0.903to1.185) | 0.582 |
| Chest discomfort or breathing difficulties | 0(0) | 4(0.1) | - | - | - | - | - | - | |
| Nausea or vomiting (no more than 5 times) | 0(0) | 30(1) | - | - | 0(0) | 10(0.3) | - | - | |
| Skin rash /urticaria | 0(0) | 54(1.8) | - | - | 0(0) | 18(0.6) | - | - | |
| Pain, swelling, redness and warmth at the injection site | 4(12.9) | 211(7.1) | 2 (0.675to5.618) | 0.217 | 3(9.7) | 140(4.7) | 1.1 (0.94to1.438) | 0.205 | |